Shine-On BioMedical Co., Ltd.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
The company’s pipeline features novel therapeutic candidates, such as precision-engineered exosomes for targeted drug delivery and nanometer-scale trispecific antibodies that engage T cells. These next-generation biologics are designed to improve the spec
Founded Year
2021
Unified Business No.
90841519
Status
Active
Number of Employees
0
Total Paid-in
Capital
498,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Exit Status
Emerging Stock Exchange(2022)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exosomes and multi-specific antibody drugs. ShineOn collaborated with worldwide renown research institutes, international capable CDMO/CRO companies and professional expert consulting groups to create new biological drugs to treat patients with cancers. According to the Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing "next-generation" targeted exosome therapeutic drugs and multi-specific antibody drugs.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
